TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16327349

Group type: EXPERIMENTAL
Intervention: Sprotte 24 g atraumatic spinal needle
Number of subjects: 342
Study: 12034928

Group type: COMPARATOR
Intervention: Ultrasonography (US) only
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) with abdominal computed tomography (CT)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) in all patients
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) in 317 patients
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Overall negative appendectomy rate
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Overall perforation rate
Number of subjects: 600
Study: 9457145

Group type: EXPERIMENTAL
Intervention: Buprenorphine (4 or 12 mg)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Buprenorphine (4 mg)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Methadone (20 or 65 mg)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 116
Study: 7631401

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intraoperative hemodilution (IH)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 2649300

Group type: EXPERIMENTAL
Intervention: 30 mg nicardipine t.i.d.
Number of subjects: 151

Group type: COMPARATOR
Intervention: 25 mg hydrochlorothiazide b.i.d.
Number of subjects: 151
Study: 37848

Group type: EXPERIMENTAL
Intervention: MIF (melanocyte-stimulating hormone-release inhibiting factor) 200 mg i.v.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study: 30797746

Group type: EXPERIMENTAL
Intervention: Endobronchial coil treatment (QVM+)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Endobronchial coil treatment (QVM-)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 125
Study: 27928851

Group type: EXPERIMENTAL
Intervention: 40 mg intravenous parecoxib
Number of subjects: 82

Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 82
Study: 26481218

Group type: EXPERIMENTAL
Intervention: Trauma card group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Direct instruction group
Number of subjects: 86
Study: 23706505

Group type: EXPERIMENTAL
Intervention: Training Group (TG) - Unilateral balance training for the right leg for six weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control Group (CG) - No training
Number of subjects: 23
Study: 21940143

Group type: EXPERIMENTAL
Intervention: Bevel-up phaco tip position
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bevel-down phaco tip position
Number of subjects: 60
Study: 19390518

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 3064

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3064

Group type: EXPERIMENTAL
Intervention: Weight loss (5 kg)
Number of subjects: 3064

Group type: EXPERIMENTAL
Intervention: Higher baseline obesity severity
Number of subjects: 3064

Group type: EXPERIMENTAL
Intervention: SF-6D improvements
Number of subjects: 3064
Study: 17544774

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydroxypropylmethylcellulose 2%
Number of subjects: 40
Study: 15592334

Group type: EXPERIMENTAL
Intervention: AMG 531 (10.0 microg/kg, intravenous)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: AMG 531 (2.0 microg/kg, subcutaneous)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: AMG 531 (1.0 microg/kg, intravenous and subcutaneous)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10812378

Group type: EXPERIMENTAL
Intervention: Modified‐fat diet high in monounsaturated fat
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low‐fat/high‐carbohydrate diet
Number of subjects: 28
Study: 8831412

Group type: EXPERIMENTAL
Intervention: 150 mg pilsicainide
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 1395659

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4006252

Group type: EXPERIMENTAL
Intervention: Dinamap 845 (D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sentron (S)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard mercury sphygmomanometer (SMS)
Number of subjects: 0
Study: 31002449

Group type: EXPERIMENTAL
Intervention: Worry condition
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Happy condition
Number of subjects: 120
Study: 30194618

Group type: EXPERIMENTAL
Intervention: Saline infusion sonohysterography (SIS)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Hysterosalpingogram (HSG)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Hysterosalpingogram (HSG) vs Saline infusion sonohysterography (SIS)
Number of subjects: 750
Study: 27907814

Group type: EXPERIMENTAL
Intervention: ASA 75mg BID
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: ASA 160mg OD
Number of subjects: 42

Group type: COMPARATOR
Intervention: ASA 75mg OD
Number of subjects: 42
Study: 25701561

Group type: EXPERIMENTAL
Intervention: Intensive five-drug cART regimen (raltegravir 400 mg and maraviroc 150 mg twice daily, plus tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, darunavir 800 mg, and ritonavir 100 mg once daily)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard triple-drug cART regimen (tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, darunavir 800 mg, and ritonavir 100 mg once daily)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Intensive five-drug cART regimen
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard triple-drug cART regimen
Number of subjects: 110
Study: 24030410

Group type: EXPERIMENTAL
Intervention: Full prescription coverage
Number of subjects: 1052

Group type: COMPARATOR
Intervention: Usual formulary coverage
Number of subjects: 1052
Study: 21398421

Group type: EXPERIMENTAL
Intervention: Migraine attack-related information
Number of subjects: 9427

Group type: EXPERIMENTAL
Intervention: Detailed migraine-specific information
Number of subjects: 9427
Study: 18182928

Group type: COMPARATOR
Intervention: Zolpidem
Number of subjects: 40

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 40
Study: 16556417

Group type: EXPERIMENTAL
Intervention: H1 group treated with BAL+MARS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: H2 group treated with BAL+SPE+CHDF
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: H3 group treated with BAL+SPE+HP
Number of subjects: 120

Group type: COMPARATOR
Intervention: C1 group treated with MARS
Number of subjects: 120

Group type: COMPARATOR
Intervention: C2 group treated with SPE+CHDF
Number of subjects: 120

Group type: COMPARATOR
Intervention: C3 group treated with SPE+HP
Number of subjects: 120
Study: 12597751

Group type: EXPERIMENTAL
Intervention: Medicare‐funded quality improvement project involving monitoring of patient outcomes, feedback of performance data, and education of clinicians at dialysis centers.
Number of subjects: 58700
Study: 10677921

Group type: EXPERIMENTAL
Intervention: Morning administration of 350 mg Euphyllin Retard at 8:00 A.M.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Evening administration of 350 mg Euphyllin Retard at 8:00 P.M.
Number of subjects: 9
Study: 8610865

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 61

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 61
Study: 1421063

Group type: EXPERIMENTAL
Intervention: Ephedrine (5 mg/dose)
Number of subjects: 36

Group type: COMPARATOR
Intervention: CaCl2 (200 mg/dose)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 3840245

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Encircling scleral buckling techniques
Number of subjects: 17
Study: 31358441

Group type: EXPERIMENTAL
Intervention: Device-applied eyelid massage (Eyepeace)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual eyelid massage
Number of subjects: 20
Study: 29400652

Group type: EXPERIMENTAL
Intervention: BuMA sirolimus-eluting stent (SES)
Number of subjects: 2348

Group type: COMPARATOR
Intervention: Excel sirolimus-eluting stent (SES)
Number of subjects: 2348
Study: 27689688

Group type: EXPERIMENTAL
Intervention: Navy beans (NB) consumption (35 g/day)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Rice bran (RB) consumption (30 g/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no additional ingredient)
Number of subjects: 29
Study: 24985882

Group type: EXPERIMENTAL
Intervention: Maintenance Rituximab (MR)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 201
Study: 21926583

Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-gluconate-impregnated sponge
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Oligon catheter
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Internal jugular catheter insertion
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Femoral catheter insertion
Number of subjects: 465
Study: 20931804

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus metformin
Number of subjects: 30
Study: 19006900

Group type: EXPERIMENTAL
Intervention: Group 2 received the lesson and watched a locally developed SBS video.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Group 3 received the lesson and watched a true dramatization of SBS created by a national organization.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Group 1 received a short lesson about SBS.
Number of subjects: 46
Study: 16115394

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - fluticasone propionate (FP) 250 microg bid for moderate asthma and 375 microg bid for severe asthma (Group G)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Inhaled corticosteroids (ICS) - half doses of fluticasone propionate (FP) 125 microg bid for moderate asthma and 125 microg in the morning, 250 microg in the evening for severe asthma (Group H)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - fluticasone propionate (FP) (Group G)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Inhaled corticosteroids (ICS) - half doses of fluticasone propionate (FP) (Group H)
Number of subjects: 86
Study: 12796125

Group type: EXPERIMENTAL
Intervention: Anti-Cp-HSP60 seropositivity
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Anti-Cp seropositivity
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Cp-HSP60 IgG levels at follow-up
Number of subjects: 339

Group type: COMPARATOR
Intervention: Correlation of Cp-HSP60 IgG with TnT and hs-CRP
Number of subjects: 339
Study: 10802126

Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg bid)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 7969211

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3659581

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31544735

Group type: EXPERIMENTAL
Intervention: Full Package community development activities
Number of subjects: 1333

Group type: COMPARATOR
Intervention: Partial Package (livestock training and nutrition education)
Number of subjects: 1333

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1333
Study: 29561511

Group type: EXPERIMENTAL
Intervention: Biannual treatment of children under 12 with azithromycin (20 mg/kg up to 1 g in adults)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Annual treatment of everyone with azithromycin (20 mg/kg up to 1 g in adults)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Biannual treatment of children under 12 with azithromycin
Number of subjects: 404
Study: 25563238

Group type: EXPERIMENTAL
Intervention: Hypotensive anaesthesia
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no hypotensive anaesthesia)
Number of subjects: 41
Study: 23579521

Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness gastroplication (Plicator group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Laparoscopic antireflux surgery (LARS group)
Number of subjects: 70
Study: 21753160

Group type: EXPERIMENTAL
Intervention: Daily prednisone (0.75 mg/kg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Weekend prednisone (10 mg/kg/wk)
Number of subjects: 64
Study: 19210142

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 16714386

Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin (r-metHuLeptin) administered during fasting
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo administered during fasting
Number of subjects: 7
Study: 15197803

Group type: EXPERIMENTAL
Intervention: Thiotepa, busulfan, and cyclophosphamide (TBC)
Number of subjects: 186

Group type: COMPARATOR
Intervention: High-dose melphalan (HDM)
Number of subjects: 186
Study: 11706112

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 782

Group type: COMPARATOR
Intervention: Levodopa plus dopa decarboxylase inhibitor
Number of subjects: 782
Study: 10567624

Group type: EXPERIMENTAL
Intervention: Inhaled ozone (200 ppb)
Number of subjects: 20
Study: 8704426

Group type: EXPERIMENTAL
Intervention: Zhuchun Pill (ZCP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (starch capsule)
Number of subjects: 45
Study: 2490739

Group type: EXPERIMENTAL
Intervention: Preparation the afternoon before surgery
Number of subjects: 23

Group type: COMPARATOR
Intervention: Preparation the morning of surgery
Number of subjects: 23
Study: 778433

Group type: EXPERIMENTAL
Intervention: Coenzyme Q7 intravenous injection (50 to 100 mg daily for 3 to 35 days)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Coenzyme Q7 oral administration (60 mg daily for 14 to 196 days)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 oral administration (30 mg daily for 7 to 182 days)
Number of subjects: 55
Study: 31820559

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 7020
Study: 31331568

Group type: EXPERIMENTAL
Intervention: Almond sachet (40 g/day for 20 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (wheat flour sachet)
Number of subjects: 50
Study: 29173737

Group type: EXPERIMENTAL
Intervention: Positive Family Interaction Therapy (PFIT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 62
Study: 26156274

Group type: COMPARATOR
Intervention: WL radiograph
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Raypex5 EAL
Number of subjects: 153
Study: 22517646

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (IP)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 95
Study: 21258153

Group type: EXPERIMENTAL
Intervention: AZD3480 5 mg
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: AZD3480 20 mg
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: AZD3480 35/100 mg
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg (active comparator)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567
Study: 19769666

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 1%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 2%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 3%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 4%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (tap water)
Number of subjects: 50
Study: 16391376

Group type: EXPERIMENTAL
Intervention: Eptifibatide (180 micro/kg bolus x 2, 10 minutes apart, then 2 micro/kg/min infusion over 18 hours)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-dose unfractionated heparin (60 Units per kg, target ACT 200-250 sec)
Number of subjects: 42

Group type: COMPARATOR
Intervention: High-dose unfractionated heparin (100 Units per kg, target ACT 300-400 sec)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Eptifibatide (LDH+I group)
Number of subjects: 42
Study: 12781889

Group type: EXPERIMENTAL
Intervention: Preservation of the great auricular nerve (GAN) during parotidectomy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Division of the great auricular nerve (GAN) during parotidectomy
Number of subjects: 81
Study: 10920165

Group type: EXPERIMENTAL
Intervention: Hypoallergenic infant formulas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard infant formulas
Number of subjects: 0
Study: 9057565

Group type: EXPERIMENTAL
Intervention: Prophylactic isoxazolyl penicillins (n=17)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No prophylactic isoxazolyl penicillins (n=21)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Total knee replacement (TKR) patients (n=21)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Total hip replacement (THR) patients (n=38)
Number of subjects: 59
Study: 8501499

Group type: EXPERIMENTAL
Intervention: Pilocarpine (2.5 mg, 5.0 mg, and 10.0 mg tablets over 12 weeks)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 3567973

Group type: COMPARATOR
Intervention: High-dose cytarabine (ara-C) 3 g/m2 infused over 2 hours
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (ara-C) 3 g/m2 infused over 2 hours with amsacrine (m-AMSA) 30 mg/m2 infused over 1 hour
Number of subjects: 11
Study: 30003598

Group type: EXPERIMENTAL
Intervention: 4.0 × 6 mm implants (test group; N = 108)
Number of subjects: 95

Group type: COMPARATOR
Intervention: 4.0 × 11 mm implants (control group; N = 101)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 4.0 × 6 mm implants (test group)
Number of subjects: 95

Group type: COMPARATOR
Intervention: 4.0 × 11 mm implants (control group)
Number of subjects: 95
Study: 27601503

Group type: EXPERIMENTAL
Intervention: Total Ankle Replacement (TAR)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Ankle Arthrodesis (fusion)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: TAR and Ankle Arthrodesis
Number of subjects: 328
Study: 23896590

Group type: EXPERIMENTAL
Intervention: Electronic documentation system
Number of subjects: 16
Study: 22851064

Group type: EXPERIMENTAL
Intervention: Epinephrine dye
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Indigo carmine dye
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Acetic acid‐indigo carmine mixture dye
Number of subjects: 699

Group type: COMPARATOR
Intervention: Conventional gastroscopic observation with white light
Number of subjects: 699

Group type: COMPARATOR
Intervention: Magnification alone
Number of subjects: 699

Group type: COMPARATOR
Intervention: Magnifying NBI observation
Number of subjects: 699
Study: 20204966

Group type: EXPERIMENTAL
Intervention: Single implementation intention
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Second implementation intention at 3 months
Number of subjects: 650

Group type: COMPARATOR
Intervention: Passive control condition
Number of subjects: 650

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: FFQ measure
Number of subjects: 650
Study: 18396390

Group type: EXPERIMENTAL
Intervention: Liquisolid tablet formulation of famotidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marketed famotidine tablets
Number of subjects: 0
Study: 15988707

Group type: EXPERIMENTAL
Intervention: Intralipid (20%) with heparin sodium
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline and heparin sodium
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline only
Number of subjects: 7
Study: 12883930

Group type: EXPERIMENTAL
Intervention: Tailored, individualised outpatient rehabilitation program for 6 weeks
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (previously trained in a home exercise program)
Number of subjects: 111
Study: 10232714

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg x kg(‐1) i.v. (Group P)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sevoflurane 8% in nitrous oxide 50% and oxygen (Group S)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Propofol (Group P)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sevoflurane (Group S)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 8780325

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-sotalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta blockers
Number of subjects: 0
Study: 1856488

Group type: EXPERIMENTAL
Intervention: Whole cell combined with cholera B subunit vaccine (WC/BS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole cell only vaccine (WC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7037152

Group type: EXPERIMENTAL
Intervention: Adriamycin and cyclophosphamide (AC)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Adriamycin, cyclophosphamide, and 5‐fluorouracil (FAC)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Adriamycin followed by cyclophosphamide, vincristine, methotrexate, 5FU, and prednisone (A + COMFP)
Number of subjects: 497
Study: 30821695

Group type: EXPERIMENTAL
Intervention: HealthyMoms smartphone app
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 300
Study: 28143867

Group type: EXPERIMENTAL
Intervention: Neoadjuvant trastuzumab
Number of subjects: 114
Study: 27506549

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328